Brief: Adalta Says FDA Assigns Orphan Drug Designation For EW-001 In Mesothelioma To Adalta
BRIEF-Adalta Says FDA Assigns Orphan Drug Designation For EW-001 In Mesothelioma To Adalta Nov 17 (Reuters) - Adalta Ltd 1AD.AX:
FDA ASSIGNS ORPHAN DRUG DESIGNATION FOR EW-001 IN MESOTHELIOMA TO ADALTA
Further company coverage: 1AD.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adalta
See all newsAustralia's AdAlta rises on FDA granting orphan drug status to lead cancer therapy
Brief: Adalta Says FDA Assigns Orphan Drug Designation For EW-001 In Mesothelioma To Adalta
Australia's AdAlta surges as partner lands up to $120 million cell therapy deal
Brief: Adalta Says Oribiotech Deal Validates Adalta Manufacturing Strategy
Brief: Adalta Says Regulatory Advisors Appointed For BZDS1901